R. Agrawal

发表

Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer in the randomised UK TACT2 trial (CRUK/05/19): a multicentre, phase 3, open-label, randomised, controlled trial

R. Laing, P. Ellis, H. Earl, 2017, The Lancet. Oncology.

Addition of gemcitabine to paclitaxel, epirubicin, and cyclophosphamide adjuvant chemotherapy for women with early-stage breast cancer (tAnGo): final 10-year follow-up of an open-label, randomised, phase 3 trial.

C. Caldas, E. Provenzano, J. Abraham, 2017, The Lancet. Oncology.

The UK Standardisation of Breast Radiotherapy (START) Trial A of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial

J. Yarnold, J. Dewar, P. Hoskin, 2008, The Lancet. Oncology.

Synchronous versus sequential chemo-radiotherapy in patients with early stage breast cancer (SECRAB): A randomised, phase III, trial

D. Rea, C. Poole, I. Ahmed, 2019, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Partial-breast radiotherapy after breast conservation surgery for patients with early breast cancer (UK IMPORT LOW trial): 5-year results from a multicentre, randomised, controlled, phase 3, non-inferiority trial

I. Ellis, P. Evans, M. Sculpher, 2017, The Lancet.

NEAT: National Epirubicin Adjuvant Trial – toxicity, delivered dose intensity and quality of life

H. Earl, D. Rea, C. Poole, 2008, British Journal of Cancer.

Abstract S4-1: The UK START (Standardisation of Breast Radiotherapy) Trials: 10-year follow-up results

J. Yarnold, J. Dewar, P. Hoskin, 2012 .

Synchronous versus sequential chemoradiotherapy in patients with early stage breast cancer (SECRAB)

D. Rea, C. Poole, I. Ahmed, 2020 .

Anglo-Celtic IV: First results of a UK National Cancer Research Network randomized phase III pharmacogenetic trial of weekly compared to 3 weekly paclitaxel in patients with locally advanced or metastatic breast cancer (ABC)

D. Cameron, A. Wardley, R. Coleman, 2007 .

The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10-year follow-up results of two randomised controlled trials.

Joanne S Haviland, John R Yarnold, J. Yarnold, 2013, The Lancet. Oncology.

The UK Standardisation of Breast Radiotherapy (START) Trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial

J R Yarnold, J. Yarnold, J. Dewar, 2008, The Lancet.

Epirubicin and cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy for early breast cancer.

H. Earl, D. Rea, S. M. Crawford, 2006, The New England journal of medicine.

Ten-Year Results of FAST: A Randomized Controlled Trial of 5-Fraction Whole-Breast Radiotherapy for Early Breast Cancer

J. Yarnold, J. Haviland, J. Bliss, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomized trial of marker-directed versus standard schedule zoledronic acid for bone metastases from breast cancer.

L. Hayward, R. Coleman, P. Simmonds, 2012 .

Cosmetic results of early breast carcinoma treated with wide local excision, external beam radiotherapy and iridium-192 boost.

S. Khanna, R. Agrawal, S. Mitchell, 1990, Journal of the Royal College of Surgeons of Edinburgh.

First results of the randomised UK FAST Trial of radiotherapy hypofractionation for treatment of early breast cancer (CRUKE/04/015).

Joanne S Haviland, John R Yarnold, J. Yarnold, 2011, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Adjuvant epirubicin followed by cyclophosphamide, methotrexate and fluorouracil (CMF) vs CMF in early breast cancer: results with over 7 years median follow-up from the randomised phase III NEAT/BR9601 trials

C. Caldas, E. Provenzano, H. Earl, 2012, British Journal of Cancer.

Explorer Adjuvant epirubicin followed by cyclophosphamide , methotrexate and fluorouracil ( CMF ) vs CMF in early breast cancer : results with over 7 years median follow-up from the randomised phase III NEAT / BR 9601 trials

C. Caldas, E. Provenzano, P. Pharoah, 2018 .

Osteonecrosis of the jaw and oral health-related quality of life after adjuvant zoledronic acid: an adjuvant zoledronic acid to reduce recurrence trial subprotocol (BIG01/04).

D. Cameron, R. Bell, Janet E Brown, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Hypofractionation for early breast cancer: First results of the UK standardization of breast radiotherapy (START) trials

J. Yarnold, J. Dewar, J. Haviland, 2007 .